Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location

Mantle Cell Lymphoma Clinical Trials

A listing of Mantle Cell Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (57) clinical trials

The ATR(ataxia-telangiectasia and Rad3 related protein) inhibitor BAY1895344 is developed for the treatment of patients with advanced solid tumors and lymphomas. The purpose of the proposed trial is to evaluate the safety and tolerability of BAY1895344, and to identify the maximum tolerated dose of BAY1895344 that could be safely given ...

Phase

Newly Diagnosed Mantle Cell Lymphoma who are not eligible for a bone marrow transplant. Patient Inclusion Criteria: 18 + years of age, diagnosis of MCL, at least 1 measurable site of disease, not eligible or not considered for bone marrow transplantation Patient Exclusion Criteria: Prior treatment with VELCADE, major surgery ...

Phase

The purpose of this study is to assess the efficacy of INCB050465 in terms of objective response rate (ORR) in subjects with mantle cell lymphoma (MCL) that is relapsed or refractory after at least 1 but no more than 3 prior systemic treatment regimens.

Phase

People with Lymphoma and Leukemia are asked to participate in a research study being conducted by Long Island Jewish Medical Center.

Phase N/A

A Trial of Ibrutinib Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma

In this trial, patients with mantle cell lymphoma will be included, treatment with lenalidomide, rituximab and ibrutinib will be administered in an induction phase for up to 12 cycles, cycle length 28 days. Patients with complete remission, partial response or stable disease will enter a maintenance phase with treatment with ...

Phase

A Trial of Obinutuzumab GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients

The study will be conducted into 2 steps for respecting the optimal safety of the OASIS trial: Step A : The primary objective of step A is to evaluate the safety of the combination of GA101 + Ibrutinib at fixed doses (560 mg per day of Ibrutinib + 1000 mg ...

Phase

Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular Marginal Zone or Mantle Cell Lymphoma.

MAGNIFY (NCT01996865) is a phase 3b, multicenter, open-label study of patients with grades 1-3b or transformed follicular lymphoma (FL), marginal zone lymphoma (MZL), or mantle cell lymphoma (MCL) who received ≥1 prior therapy and had stage I-IV, measurable disease. ~500 patients are planned for enrollment in 12 cycles of R2 ...

Phase

Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer

PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) of everolimus when administered in combination with bendamustine (bendamustine hydrochloride) in defined hematologic malignancies. II. To determine the safety and tolerability of administering everolimus in combination with bendamustine chemotherapy. SECONDARY OBJECTIVES: I. To determine the efficacy of everolimus when administered ...

Phase

Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma

PRIMARY OBJECTIVES: I. To determine the progression-free survival (PFS) rate after 2 years. SECONDARY OBJECTIVES: I. Assess toxicity. II. Determine rates of conversion from partial response (PR) to complete response (CR). III. Determine median overall survival (OS) after 4 years. TERTIARY OBJECTIVES: I. Compare minimal residual disease (MRD) results overtime ...

Phase

Vincristine Sulfate Liposome Injection (Marqibo ) Bendamustine and Rituximab Phase I Trial in Indolent B-cell Lymphoma

Bendamustine-rituximab is a standard chemotherapy regimen for treatment of many indolent B-cell lymphomas, but most patients experience a recurrence of the lymphoma. Vincristine sulfate has been a traditional component of chemotherapy regimens in non-Hodgkin lymphoma and it is possible that adding it to the bendamustine-rituximab regimen might provide a better ...

Phase